Evidence map›Paper›PMID 26018161›Full record

ArticleJournal of virology2015

Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins.

Susanna L Lamers, Ruchi M Newman, Oliver Laeyendecker, Aaron A R Tobian, Robert C Colgrove, Stuart C Ray, David M Koelle, Jeffrey Cohen, David M Knipe, Thomas C Quinn

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Marine drugs · 2023
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Multiple Class I and Class II Haemophilus ducreyi Strains Cause Cutaneous Ulcers in Children on an Endemic Island.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Susanna L LamersBioinfoexperts, LLC, Thibodaux, Louisiana, USA susanna@bioinfox.com.
Ruchi M NewmanBroad Institute, Boston, Massachusetts, USA.
Oliver LaeyendeckerLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Aaron A R TobianLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Robert C ColgroveDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA Department of Medicine, Mount Auburn Hospital, Cambridge, Massachusetts, USA.
Stuart C RayDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
David M KoelleDepartments of Medicine, Laboratory Medicine, and Global Health, University of Washington, Seattle, Washington, USA Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Jeffrey CohenLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
David M KnipeDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA.
Thomas C QuinnLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA Department of Medicine, Mount Auburn Hospital, Cambridge, Massachusetts, USA.
Harvard University · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USBroad Institute · USFred Hutch Cancer Center · USJohns Hopkins University · US

Funding

THE PERINATAL COMPLICATIONS OF ASYMPTOMATIC GENITAL HERPES SIMPLEX VIRUSP01AI030731 · NIAID · UNIVERSITY OF WASHINGTON · PI ZHU, JIA · 1991 to 2017
$34.3M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Herpesvirus Pathogenesis and Vaccine DevelopmentZIAAI000978 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI COHEN, JEFFREY · 2009 to 2025
$13.7M
Development Of Vaccines For Genital Herpes Simplex InfectionZIAAI000548 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI COHEN, JEFFREY · 2009 to 2025
$12.1M
Pathogenesis and Chemotherapy of Human Virus InfectionsZIAAI000058 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI COHEN, JEFFREY · 2009 to 2025
$8.8M
Immunopathogenesis Of Chlamydia trachomatis InfectionZIAAI000358 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI QUINN, THOMAS · 2009 to 2022
$7.0M
International Herpes Vaccine ProjectR01AI057552 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KNIPE, DAVID M. · 2005 to 2014
$3.8M
Genomic systems approach to measure HSV-1-specific T-cell dominance in humansR01AI094019 · NIAID · UNIVERSITY OF WASHINGTON · PI KOELLE, DAVID M · 2012 to 2016
$1.9M
International Herpes Vaccine ProjectR56AI057552 · NIAID · HARVARD MEDICAL SCHOOL · PI KNIPE, DAVID M. · 2011 to 2011
$70k
Intramural NIH HHSNIAID NIH HHS AI030731NIAID NIH HHS AI057552NIAID NIH HHS AI094019NIAID NIH HHS HHSN272200900018CNIAID NIH HHS P01 AI030731NIAID NIH HHS R01 AI057552NIAID NIH HHS R01 AI094019NIAID NIH HHS R56 AI057552
6 · The paper itself

Abstract

unlabelledHuman herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) are large-genome DNA viruses that establish a persistent infection in sensory neurons and commonly manifest with recurring oral or genital erosions that transmit virus. HSV encodes 12 predicted glycoproteins that serve various functions, including cellular attachment, entry, and egress. Glycoprotein G is currently the target of an antibody test to differentiate HSV-1 from HSV-2; however, this test has shown reduced capacity to differentiate HSV strains in East Africa. Until the recent availability of 26 full-length HSV-1 and 36 full-length HSV-2 sequences, minimal comparative information was available for these viruses. In this study, we use a variety of sequence analysis methods to compare all available sequence data for HSV-1 and HSV-2 glycoproteins, using viruses isolated in Europe, Asia, North America, the Republic of South Africa, and East Africa. We found numerous differences in diversity, nonsynonymous/synonymous substitution rates, and recombination rates between HSV-1 glycoproteins and their HSV-2 counterparts. Phylogenetic analysis revealed that while most global HSV-2 glycoprotein G sequences did not form clusters within or between continents, one clade (supported at 60.5%) contained 37% of the African sequences analyzed. Accordingly, sequences from this African subset contained unique amino acid signatures, not only in glycoprotein G, but also in glycoproteins I and E, which may account for the failure of sensitive antibody tests to distinguish HSV-1 from HSV-2 in some African individuals. Consensus sequences generated in the study can be used to improve diagnostic assays that differentiate HSV-1 from HSV-2 in global populations. IMPORTANCE: Human herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) are large DNA viruses associated with recurring oral or genital erosions that transmit virus. Up to 12 HSV-1 and HSV-2 glycoproteins are involved in HSV cell entry or are required for viral spread in animals, albeit some are dispensable for replication in vitro. The recent availability of comparable numbers of full-length HSV-1 and HSV-2 sequences enabled comparative analysis of gene diversity of glycoproteins within and between HSV types. Overall, we found less glycoprotein sequence diversity within HSV-2 than within the HSV-1 strains studied, while at the same time, several HSV-2 glycoproteins were evolving under less selective pressure. Because HSV glycoproteins are the focus of antibody tests to detect and differentiate between infections with the two strains and are constituents of vaccines in clinical-stage development, these findings will aid in refining the targets for diagnostic tests and vaccines.

Indexed as

AnimalsGlycoproteinsHerpesvirus 1, HumanHerpesvirus 2, HumanHumansPhylogenyViral ProteinsGlycoproteinsViral Proteins

Identifiers

PMID26018161
PMCPMC4524236
OpenAlexW2112926206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.